Pharmaceutical composition for treating or preventing cancer
A pharmaceutical composition targeting COPB2 with antibodies effectively inhibits cancer cell proliferation and metastasis, addressing the limitations of existing COPB2 research by providing a targeted approach for cancer treatment and prevention.
Patent Information
- Application Number
- PCT/JP2024/018033
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-15
- Publication Date
- 2024-11-28
AI Technical Summary
Current research on COPB2 has been limited to physiological functional analysis as an intracellular protein, and there is a need for a targeted pharmaceutical composition to treat or prevent cancer effectively.
A pharmaceutical composition comprising antibodies against coatomer protein complex subunit beta 2 (COPB2) or its antigen-binding fragments, specifically designed to target and inhibit COPB2, thereby suppressing cancer growth, metastasis, and recurrence in various cancer types such as breast, glioma, and hepatocellular carcinoma.
The antibodies effectively bind to COPB2, inhibiting its expression and activity, leading to reduced cancer cell proliferation, metastasis, and apoptosis induction in cancer cells, demonstrating significant therapeutic potential for treating and preventing cancer.
Smart Images

Figure 000058 
Figure 000059 
Figure 000060
Abstract
Description
Pharmaceutical composition for treating or preventing cancer
[0001] The present invention relates to a pharmaceutical composition for treating or preventing cancer.
[0002] Coatomer protein complex subunit beta 2 (COPB2) is one of the non-clathrin-coated endoplasmic reticulum subunits that form coatomers involved in membrane transport between the endoplasmic reticulum and the Golgi apparatus in cells.
[0003] Non-Patent Document 1 discloses that COPB2, as a coatomer protein, plays an important role in embryonic development and tumor progression, is involved in various pathologies, and is also involved in the regulation of cancer cell proliferation, survival, invasion, and metastasis, and therefore is being studied as an important factor in many cancers. Non-Patent Document 2 discloses that COPB2 is highly expressed in gliomas, and that high COPB2 expression correlates with shorter overall survival and several poor clinical prognostic variables. Non-Patent Document 2 also discloses that COPB2 can be a potential prognostic biomarker and a target for glioma immunotherapy. Non-Patent Document 3 discloses that COPB2 is overexpressed in hepatocellular carcinoma (HCC), and that silencing COPB2 inhibits epithelial-mesenchymal transition and mTOR signaling, thereby inhibiting the proliferation, migration, and invasion of HCC. Furthermore, Non-Patent Document 3 discloses that COPB2 is a novel prognostic biomarker and a potential therapeutic target for HCC. Non-Patent Document 4 discloses that the COPB2 gene is overexpressed in breast cancer tissues, and that downregulation of COPB2 can inhibit the proliferation and invasive abilities of MDA-MB-231 and BT-549 cell lines. Non-Patent Document 5 discloses that COPB2 is highly expressed in lung adenocarcinoma cells, and that silencing COPB2 suppresses cell viability and metastasis and significantly increases apoptosis. Non-Patent Document 6 discloses that silencing the COPB2 gene can inhibit the proliferation of colorectal cancer (CRC) cells and induce apoptosis via the JNK / c-Jun signaling pathway. Non-Patent Document 7 discloses that miR-4461 derived from bone marrow mesenchymal stem cell exosomes downregulates COPB2 expression and suppresses the migration and invasion of colon cancer cells. Non-Patent Document 9 discloses that miR-4461 can be a potential target for the diagnosis and treatment of colorectal cancer (colon / rectum). Non-Patent Document 8 discloses that silencing of COPB2 inhibits the proliferation of gastric cancer cells and induces apoptosis through suppression of the RTK signaling pathway.Non-Patent Document 9 discloses that COPB2 was identified as a differentially expressed mRNA that was downregulated after treatment of gastric cancer cells with chrysin, which has antitumor properties. Non-Patent Document 10 discloses that COPB2 is upregulated in prostate cancer and regulates PC-3 cell proliferation, cell cycle, and apoptosis.
[0004] Clin Transl Oncol, 2021(11):2195-2205.CNS Neuroscience&Therapeutics, 2020, March;26(3):309-318.BioMed Research International; 2021:6648078.J Cell Mol Med. 2019 Aug;23(8):5235-5245.Transl Cancer Res.2020April;9(4):2648-2659.PLoS One, November 19, 2020:e0240106.Biosci Biotechnol Biochem. 2020 Feb;84(2):338-346.2019 Oct 21.Int J Oncol. 2019 Apr;54(4):1195-1208.Front Oncol. 2021 Jun 3;11:651644.Arch Med Res. 2016 Aug;47(6):411-418.
[0005] As described above, research reports have been published on the relationship between COPB2 and various cancers. However, these studies have been limited to analyzing the physiological function of COPB2 as an intracellular protein by silencing the COPB2 gene, etc. The present invention aims to provide a new pharmaceutical composition for treating or preventing cancer by targeting COPB2.
[0006] As a result of extensive research, the present inventors have surprisingly found that antibodies against COPB2, an intracellular protein, are effective in treating cancer and inhibiting metastasis, and have thus completed the present invention.
[0007] That is, the present invention is as follows: [1] A pharmaceutical composition for treating or preventing cancer, comprising an antibody against coatomer protein complex subunit beta 2 (COPB2) or an antigen-binding fragment thereof. [2] The pharmaceutical composition according to [1], wherein the cancer is a primary tumor. [3] The pharmaceutical composition according to [1] or [2], wherein the cancer is a primary tumor. [4] The pharmaceutical composition according to any of [1] to [3], wherein the cancer is one or more selected from the group consisting of breast cancer, glioma, gastrointestinal cancer, hepatocellular carcinoma, liver cancer, prostate cancer, lung cancer, and pancreatic cancer. [5] The pharmaceutical composition according to any of [1] to [4], wherein the cancer is one or more selected from the group consisting of breast cancer, glioma, gastrointestinal cancer, hepatocellular carcinoma, liver cancer, prostate cancer, lung cancer, and pancreatic cancer.
[0008] The present invention also includes the following aspects. [A1] A method for treating or preventing cancer, comprising administering to a patient in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof against coatomer protein complex subunit beta 2 (COPB2). [A2] The method according to [A1], wherein the cancer is a primary tumor. [A3] The method according to [A1] or [A2], for suppressing cancer recurrence. [A4] The method according to any of [A1] to [A3], for suppressing cancer metastasis. [A5] The method according to any of [A1] to [A4], wherein the cancer is one or more selected from the group consisting of breast cancer, glioma, gastrointestinal cancer, hepatocellular carcinoma, liver cancer, prostate cancer, lung cancer, and pancreatic cancer.
[0009] [B1] An antibody or antigen-binding fragment thereof against coatomer protein complex subunit beta 2 (COPB2) for treating or preventing cancer. [B2] The antibody or antigen-binding fragment thereof according to [B1], wherein the cancer is a primary tumor. [B3] The antibody or antigen-binding fragment thereof according to [B1] or [B2], for suppressing cancer recurrence. [B4] The antibody or antigen-binding fragment thereof according to any of [B1] to [B3], for suppressing cancer metastasis. [B5] The antibody or antigen-binding fragment thereof according to any of [B1] to [B4], wherein the cancer is one or more selected from the group consisting of breast cancer, glioma, gastrointestinal cancer, hepatocellular carcinoma, liver cancer, prostate cancer, lung cancer, and pancreatic cancer.
[0010] [C1] Use of an antibody or antigen-binding fragment thereof against coatomer protein complex subunit beta 2 (COPB2) for treating or preventing cancer. [C2] The use according to [C1], wherein the cancer is a primary tumor. [C3] The use according to [C1] or [C2], for suppressing cancer recurrence. [C4] The use according to any of [C1] to [C3], for suppressing cancer metastasis. [C5] The use according to any of [C1] to [C4], wherein the cancer is one or more selected from the group consisting of breast cancer, glioma, gastrointestinal cancer, hepatocellular carcinoma, liver cancer, prostate cancer, lung cancer, and pancreatic cancer.
[0011] [D1] Use of an antibody or antigen-binding fragment thereof against coatomer protein complex subunit beta 2 (COPB2) in the manufacture of a pharmaceutical composition for treating or preventing cancer. [D2] The use according to [D1], wherein the cancer is a primary tumor. [D3] The use according to [D1] or [D2], in the manufacture of a pharmaceutical composition for suppressing cancer recurrence. [D4] The use according to any of [D1] to [D3], in the manufacture of a pharmaceutical composition for suppressing cancer metastasis. [D5] The use according to any of [D1] to [D4], wherein the cancer is one or more selected from the group consisting of breast cancer, glioma, gastrointestinal cancer, hepatocellular carcinoma, liver cancer, prostate cancer, lung cancer, and pancreatic cancer.
[0012] In any of the inventions [1] to [5], [A1] to [A5], [B1] to [B5], [C1] to [C5], and [D1] to [D5], the configuration of the invention, such as an antibody or antigen-binding fragment thereof against coatomer protein complex subunit beta 2 (COPB2), may be any of the preferred embodiments described below as the present embodiments. Furthermore, in any of the inventions [1] to [5], [A1] to [A5], [B1] to [B5], [C1] to [C5], and [D1] to [D5], the configuration of the invention may be selected from any combination of the preferred embodiments described below as the present embodiments. Preferred embodiments include more preferred embodiments, even more preferred embodiments, and even more preferred embodiments.
[0013] According to the present invention, a pharmaceutical composition for treating or preventing cancer, which comprises an antibody against COPB2 or an antigen-binding fragment thereof, can be provided.
[0014] This figure shows the principle of antibody titer measurement after immunization with purified human COPB2 (650-906) protein in mice. This figure also shows antibody titers after two immunizations with purified human COPB2 protein in mice. A / Jackson mice all showed high antibody titers of over 800,000 counts, while Balb / c mice showed antibody titers of less than 200,000 counts. This figure shows an investigation into whether COPB2 protein can be detected in human and mouse cells by Western blotting. Lane 1: 10 μg of HEK293 cell extract; Lane 2: 5 μg of mouse liver extract; Lane 3: 10 μg of mouse liver extract. The amino acid sequences of the heavy chain CDRs 1 to 3 and light chain CDRs 1 to 3 of clone A2-7C6 (Figure 4A) and the amino acid sequences of the heavy chain variable region and light chain variable region (Figure 4B) are shown. The amino acid sequences of the heavy chain CDR1-3 and light chain CDR1-3 of clone A2-7D11 (Figure 5A) and the amino acid sequences of the heavy chain variable region and light chain variable region (Figure 5B) are shown. The amino acid sequences of the heavy chain CDR1-3 and light chain CDR1-3 of clone A3-8C9 (Figure 6A) and the amino acid sequences of the heavy chain variable region and light chain variable region (Figure 6B) are shown. The luminescence intensity from breast cancer cells is shown. IVIS measurement images of primary tumors are shown. It was confirmed that the luminescence intensity was lower in the group administered with anti-COPB2 antibody than in the control group. IVIS measurement results of primary tumors are shown. It was confirmed that the luminescence intensity was lower in the group administered with anti-COPB2 antibody than in the control group. IVIS measurement images of the whole body of a breast cancer model mouse after primary tumor removal are shown. It was confirmed that the luminescence intensity was lower in the group administered with anti-COPB2 antibody than in the control group. The results of whole-body IVIS measurements of breast cancer model mice after primary tumor removal (FIG. 11A) and the number of metastatic lesions (FIG. 11B) are shown. It was confirmed that the anti-COPB2 antibody-administered group had lower luminescence and fewer metastatic lesions than the control group. The full-length amino acid sequence of human COPB2 is shown. The amino acid sequences of heavy chain CDR1-3 and light chain CDR1-3 of clone TA201C003a (identification number: #003) are shown (FIG. 13A), as well as the amino acid sequences of the heavy chain variable region and light chain variable region (FIG. 13B).The amino acid sequences of the heavy chain CDRs 1-3 and light chain CDRs 1-3 of clone TA201B010a (identification number: #010) are shown (Figure 14A), as well as the amino acid sequences of the heavy chain variable region and light chain variable region (Figure 14B). The antibody titers of TC-mAb mice after two immunizations with purified human COPB2 protein are shown. Analysis of the antisera confirmed elevated titers in all immunized individuals. The absorbance of the top-ranked clones in the secondary screening is shown. Cloning was performed by limiting dilution, and ELISA was performed on the culture supernatant using two immobilized antigens, one derived from E. coli and one derived from animal. The results of SDS-PAGE of purified human monoclonal antibodies are shown. The results of a sample treated with the reducing agent DTT (DTT+) were compared with those of an untreated sample (DTT-). The ELISA results of purified human monoclonal antibodies are shown. These results demonstrated that the titer of identification number: #010,002,007 was high. Note that identification number #009 appears to have failed to adapt to serum-free medium, resulting in only small amounts of purified antibody. The purified antibody likely contained many contaminating proteins, which is likely why the ELISA titer was low. Western blotting analysis of human monoclonal antibodies demonstrates COPB2 reactivity. All five antibodies were shown to react with human COPB2. TA201C003a and TA201B008a were confirmed to be specific for human COPB2 and not with mouse COPB2. TA201B010a was confirmed to react strongly with both human and mouse COPB2. TA201B007a and TA201C002a were confirmed to react more strongly with mouse COPB2 than with human COPB2. Results from the human isotyping kit are shown. The purified human monoclonal antibodies, identification numbers #003 and #010, were both confirmed to be of the IgG1 / kappa subclass. The results of the cell-killing effect (cell viability) and apoptosis-inducing effect (caspase 3 / 7 activity) of anti-COPB2 antibodies on breast cancer cells are shown. Human breast cancer cells (MDA-MB-231-D3H2LN) cultured in medium containing a high concentration (20 μM) of the TA201B010a clone showed a significant decrease in viability compared to cells cultured in medium containing only PBS (-).Furthermore, a significant decrease in caspase 3 / 7 activity was confirmed in cells cultured in a medium containing high concentrations of the TA201B010a clone and the TA201C003a clone.
[0015] Hereinafter, embodiments of the present invention will be described, but the present invention is not limited to the following examples.
[0016] (Anti-COPB2 antibody or antigen-binding fragment thereof) In this specification, an antibody against coatomer protein complex subunit beta2 is also referred to as an anti-COPB2 antibody. The description of an anti-COPB2 antibody also applies to an antigen-binding fragment of an anti-COPB2 antibody. Therefore, in this specification, even if there is no mention of an antigen-binding fragment of an anti-COPB2 antibody, the description of an anti-COPB2 antibody will be understood as a description of an antigen-binding fragment of an anti-COPB2 antibody.
[0017] COPB2 is a protein that is widely conserved from yeast to humans. In one embodiment, the anti-COPB2 antibody specifically binds to human COPB2, and the antigen-binding fragment of the anti-COPB2 antibody may also specifically bind to human COPB2.
[0018] The anti-COPB2 antibody may be any antibody that specifically binds to human COPB2 and inhibits the activity of human COPB2, and examples thereof include antibodies that bind to human COPB2 and thereby prevent human COPB2 from binding to the human COPB2 receptor.
[0019] The binding site of COPB2 to which the anti-COPB2 antibody binds is not particularly limited, but it is preferable that the antibody binds to, for example, one or more peptides having the amino acid sequence of human COPB2.
[0020] Furthermore, the inventors speculate that the reason why anti-COPB2 antibodies are effective in treating or preventing cancer is as follows, although this is not intended to be limiting. Specifically, administration of an anti-COPB2 antibody specifically binds to COPB2, suppressing COPB2 expression and inhibiting binding to the human COPB2 receptor. This is thought to inhibit cancer growth and induce apoptosis in cancer cells. It is also thought that exosome secretion from cancer cells is suppressed.
[0021] As used herein, the term "antibody" refers to a molecule having a structure in which two heavy chains (H chains) and two light chains (L chains) are associated and stabilized by a pair of disulfide bonds. Each of the two heavy chains consists of a heavy chain variable region VH, heavy chain constant regions CH1, CH2, and CH3, and a hinge region located between CH1 and CH2. The light chain consists of a light chain variable region VL and a light chain constant region CL. In an antibody, the variable region fragment (Fv) consisting of VH and VL is the region directly involved in binding to an antigen. The antigen-binding region consisting of VL, CL, VH, and CH1 is called the Fab region, and the region consisting of the hinge region, CH2, and CH3 is called the Fc region.
[0022] Within the variable region, the region that directly contacts the antigen undergoes particularly large changes and is called the complementarity-determining region (CDR). The portion other than the CDR that shows relatively little variation is called the framework region (FR). The light chain and heavy chain variable regions each contain three CDRs (heavy chain CDRs 1 to 3, and light chain CDRs 1 to 3).
[0023] The anti-COPB2 antibody is not particularly limited, and may be, for example, a monoclonal antibody or a polyclonal antibody.
[0024] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, produced, for example, by hybridoma methods, recombinant DNA methods, phage display methods, or methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, or a combination thereof, without limitation.
[0025] As used herein, the term "polyclonal antibody" refers to a mixture of different antibodies that recognize multiple epitopes on a single antigen. Polyclonal antibodies are produced, but are not limited to, by administering an immunogen containing the antigen of interest to mammals (e.g., rats, mice, rabbits, cows, monkeys, etc.) or birds (e.g., chickens, etc.).
[0026] As used herein, the term "epitope" refers to a site (antigenic determinant) that is recognized by the immune system when a substance elicits antibodies against it (antigen).
[0027] The anti-COPB2 antibody may be conjugated with another drug, forming an antibody-drug conjugate (ADC). Examples of other drugs that can be used to form an ADC include, but are not limited to, tubulin synthesis inhibitors (anticancer plant alkaloids), alkylating agents that are inhibitors of nucleic acid synthesis, topoisomerase inhibitors, antimetabolites, anticancer antibiotics, hormone preparations, platinum preparations, and nonspecific antineoplastic agents. Examples of tubulin synthesis inhibitors (anticancer plant alkaloids) include, but are not limited to, auristatins, vincristine sulfate, vinblastine sulfate, vindesine sulfate, docetaxel hydrate, paclitaxel, vinorelbine tartrate, and maytansinoids. Examples of alkylating agents include, but are not limited to, cyclophosphamide, ifosfamide, melphalan, thioteva, busulfan, carboquone, dacarbazine, nimustine hydrochloride, and ranimustine. Examples of topoisomerase inhibitors include, but are not limited to, camptothecin, topotecan, etoposide, irinotecan hydrochloride, nogitecan hydrochloride, etc. Examples of antimetabolites include, but are not limited to, methotrexate, mercaptopurine, 6-mercaptopurine riboside, fluorouracil (5-FU), tegafur, tegafur uracil, carmofur, doxifluridine, cytarabine ocfosfate, hydroxycarbamide, cytarabine, gemcitabine hydrochloride, fludarabine phosphate, enocitabine, leucovorin, etc. Anticancer antibiotics include, but are not limited to, doxorubicin hydrochloride, idarubicin hydrochloride, epirubicin hydrochloride, pirarubicin hydrochloride, daunorubicin hydrochloride, aclarubicin hydrochloride, mitomycin C, actinomycin D, bleomycin, peplomycin sulfate, neocarzinostatin, zinostatin stimalamer, etc. Hormonal preparations include, but are not limited to, estramustine phosphate sodium, flutamide, bicalutamide, goserelin acetate, neuprorelin acetate, tamoxifen citrate, fodrozole hydrochloride hydrate, anastrozole, mepitiostane, epitiostanol, medroxyprogesterone acetate, etc.Platinum preparations include, but are not limited to, cisplatin, carboplatin, nedaplatin, etc. Non-specific antineoplastic agents include, but are not limited to, krestin, lenatin, sizofiran, ubenimex, etc. Other drugs include, but are not limited to, mitoxantrone hydrochloride, procarbazine hydrochloride, pentostatin, sobuzoxane, tretinoin, L-asparaginase, aceglatone, mitotane, porfimer sodium, etc.
[0028] As used herein, the term "antigen-binding fragment" refers to a molecule that contains a portion of an antibody and is capable of binding to the same antigen as the antibody. Examples of antigen-binding fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, diabody, linear antibody, and single-chain antibody molecule (e.g., scFv).
[0029] As used herein, the term "bispecific antibody" refers to a bispecific antibody that can bind to two types of antigens with a single antibody, and includes, but is not limited to, bioengineered antibodies.
[0030] As used herein, the term "nucleotide" or "polynucleotide" refers to nucleic acids, including, but not limited to, DNA, RNA, probes, oligonucleotides, and primers.
[0031] As used herein, the term "expression vector" refers to a transduction element required to express a gene of interest, and includes, but is not limited to, plasmids and viruses such as bacteriophages.
[0032] Anti-COPB2 antibodies may have a structure known as an antibody and may be any of the isotypes IgG, IgM, IgA, IgD, or IgE. IgG is an immunoglobulin with a gamma heavy chain and is produced as part of a secondary immune response to an antigen. IgM is an immunoglobulin with a mu heavy chain and exists as a pentamer in mammals. IgA is an immunoglobulin with an alpha heavy chain, IgD is an immunoglobulin with an epsilon heavy chain, and IgE is an immunoglobulin with a delta heavy chain.
[0033] The anti-COPB2 antibody may be a chimeric antibody, a humanized antibody, a human antibody, or the like. The antigen-binding fragment of the anti-COPB2 antibody may be an antigen-binding fragment of a chimeric antibody, an antigen-binding fragment of a humanized antibody, an antigen-binding fragment of a human antibody, or the like. A chimeric antibody is an antibody in which fragments of antibodies derived from different species are linked. A humanized antibody is an antibody in which non-human CDR amino acid sequences are grafted onto a human antibody. Examples of humanized antibodies include, but are not limited to, antibodies having heavy chain CDRs 1-3 and light chain CDRs 1-3 of an antibody produced by immunizing a mouse or rat, with all other regions derived from a human antibody. The term "humanized antibody" may also refer to a human chimeric antibody, a mutated human antibody, and a human-type antibody.
[0034] In one aspect of this embodiment, the anti-COPB2 antibody or antigen-binding fragment thereof may comprise any of the following sets of CDRs (a) to (e): (a) a heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 1; a heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 2; a heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 3; a light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 4; a light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 5, and a light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 6; (b) a heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 7; a heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 8; a heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 9; a light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 10; a light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 11, and a light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 12; (c) a heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 13; a heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 14; a heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 15; a light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 16 (d) a light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 17, and a light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 18; (d) a heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 32; a heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 33; a heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 34; a light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 35; a light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 36, and a light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 37; (e) a heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 38; a heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 39; a heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 40; a light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 41; a light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 42, and a light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 43
[0035] The anti-COPB2 antibody or antigen-binding fragment thereof is capable of specifically binding to COPB2 by having any of the above CDR sets (a) to (e).
[0036] In one aspect of this embodiment, the anti-COPB2 antibody or antigen-binding fragment thereof may comprise any of the following sets of CDRs (a1) to (e1): (a1) a heavy chain CDR1 which is the amino acid sequence represented by SEQ ID NO: 1 or which contains the amino acid sequence represented by SEQ ID NO: 1 with one to several amino acid additions, substitutions, or deletions; a heavy chain CDR2 which is the amino acid sequence represented by SEQ ID NO: 2 or which contains the amino acid sequence represented by SEQ ID NO: 2 with one to several amino acid additions, substitutions, or deletions; a heavy chain CDR3 which is the amino acid sequence represented by SEQ ID NO: 3 or which contains the amino acid sequence represented by SEQ ID NO: 3 with one to several amino acid additions, substitutions, or deletions; a light chain CDR1 which is the amino acid sequence represented by SEQ ID NO: 4 or which contains the amino acid sequence represented by SEQ ID NO: 4 with one to several amino acid additions, substitutions, or deletions; a light chain CDR2 which is the amino acid sequence represented by SEQ ID NO: 5 or which contains the amino acid sequence represented by SEQ ID NO: 5 with one to several amino acid additions, substitutions, or deletions; and a light chain CDR3 which is the amino acid sequence represented by SEQ ID NO: 6 or which contains the amino acid sequence represented by SEQ ID NO: 6 with one to several amino acid additions, substitutions, or deletions. (b1) Heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 7 or the amino acid sequence represented by SEQ ID NO: 7 with one to several amino acid additions, substitutions, or deletions. Heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 8 or the amino acid sequence represented by SEQ ID NO: 8 with one to several amino acid additions, substitutions, or deletions. Heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 9 or the amino acid sequence represented by SEQ ID NO: 9 with one to several amino acid additions, substitutions, or deletions. Light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 10 or the amino acid sequence represented by SEQ ID NO: 10 with one to several amino acid additions, substitutions, or deletions.a light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 11 or the amino acid sequence represented by SEQ ID NO: 11 with one to several amino acid additions, substitutions, or deletions; and a light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 12 or the amino acid sequence represented by SEQ ID NO: 12 with one to several amino acid additions, substitutions, or deletions. (c1) a heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 13 or the amino acid sequence represented by SEQ ID NO: 13 with one to several amino acid additions, substitutions, or deletions. a heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 14 or the amino acid sequence represented by SEQ ID NO: 14 with one to several amino acid additions, substitutions, or deletions. a heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 15 or the amino acid sequence represented by SEQ ID NO: 15 with one to several amino acid additions, substitutions, or deletions. a light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 16 or the amino acid sequence represented by SEQ ID NO: 16 with one to several amino acid additions, substitutions or deletions; a light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 17 or the amino acid sequence represented by SEQ ID NO: 17 with one to several amino acid additions, substitutions or deletions; and a light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 18 or the amino acid sequence represented by SEQ ID NO: 18 with one to several amino acid additions, substitutions or deletions. (d1) a heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 32 or the amino acid sequence represented by SEQ ID NO: 32 with one to several amino acid additions, substitutions or deletions; and a heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 33 or the amino acid sequence represented by SEQ ID NO: 33 with one to several amino acid additions, substitutions or deletions. A heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 34 or the amino acid sequence represented by SEQ ID NO: 34 with one to several amino acid additions, substitutions, or deletions.a light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 35 or the amino acid sequence represented by SEQ ID NO: 35 with one to several amino acid additions, substitutions or deletions; a light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 36 or the amino acid sequence represented by SEQ ID NO: 36 with one to several amino acid additions, substitutions or deletions; and a light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 37 or the amino acid sequence represented by SEQ ID NO: 37 with one to several amino acid additions, substitutions or deletions. (e1) a heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 38 or the amino acid sequence represented by SEQ ID NO: 38 with one to several amino acid additions, substitutions or deletions; and a heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 39 or the amino acid sequence represented by SEQ ID NO: 39 with one to several amino acid additions, substitutions or deletions. a heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 40 or the amino acid sequence represented by SEQ ID NO: 40 with one to several amino acid additions, substitutions, or deletions; a light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 41 or the amino acid sequence represented by SEQ ID NO: 41 with one to several amino acid additions, substitutions, or deletions; a light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 42 or the amino acid sequence represented by SEQ ID NO: 42 with one to several amino acid additions, substitutions, or deletions; and a light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 43 or the amino acid sequence represented by SEQ ID NO: 43 with one to several amino acid additions, substitutions, or deletions.
[0037] The anti-COPB2 antibody is preferably an antibody comprising any one of the above CDR sets (a) to (e), but may also be an antibody comprising any one of the above CDR sets (a1) to (e1). That is, the above explanation should be understood as meaning that the antigen-binding fragment of the anti-COPB2 antibody is preferably an antigen-binding fragment comprising any one of the above CDR sets (a) to (e), but may also be an antigen-binding fragment comprising any one of the above CDR sets (a1) to (e1). In the above CDR sets (a1) to (e1), the heavy chain CDR1 to CDR3 and the light chain CDR1 to CDR3 may be any one of the above CDR sets (a) to (e). In the set of CDRs (a1) to (e1) above, the amino acid sequence of any of the CDRs may be an amino acid sequence represented by SEQ ID NOs: 1 to 6, which contains one to several amino acid additions, substitutions, or deletions, and the number of CDRs which contain one to several amino acid additions, substitutions, or deletions may be 1 to 6.
[0038] When an anti-COPB2 antibody or an antigen-binding fragment thereof has any of the CDR sets (a1) to (e1) above, the antibody or antigen-binding fragment thereof has or retains the ability to bind to COPB2 in any of the CDR sets.
[0039] As used herein, when the phrase "including addition, substitution, or deletion of one to several amino acids" is used, the number of amino acids to be added, substituted, or deleted may be, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0040] When the phrase "contains one to several amino acid additions, substitutions, or deletions" is used in reference to the amino acid sequence of a CDR, the number of added, substituted, or deleted amino acids is not particularly limited as long as the anti-COPB2 antibody has the ability to bind to COPB2, and may be, for example, one, two, three, or four. The phrase may include "one amino acid addition, substitution, or deletion," "one to two amino acid additions, substitutions, or deletions," "one to three amino acid additions or deletions," or "one to four amino acid additions, substitutions, or deletions." In reference to the amino acid sequence of a CDR, "one to two amino acid additions, substitutions, or deletions" is preferred, and "one amino acid addition, substitution, or deletion" is more preferred.
[0041] The position of the amino acid addition, substitution, or deletion may be anywhere in the amino acid sequence of the CDR, as long as the binding to COPB2 is maintained. The heavy chain variable region and light chain variable region of an antibody comprise, from N-terminus to C-terminus, FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4, with heavy chain CDR3 being particularly important for determining the antigen specificity of the antibody. When an anti-COPB2 antibody has a mutation in a CDR, one to several amino acid additions, substitutions, or deletions may be made in CDR1 and / or CDR2 other than CDR3, as long as the antibody maintains its antigen specificity, and the addition, substitution, or deletion may be a single amino acid.
[0042] In one aspect of this embodiment, the anti-COPB2 antibody or antigen-binding fragment thereof may comprise any of the following sets of CDRs (a2) to (e2): (a2) a heavy chain CDR1 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 1; a heavy chain CDR2 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 2; a heavy chain CDR3 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 3; a light chain CDR1 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 4; a light chain CDR2 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 5; and a light chain CDR3 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 6. (b2) a heavy chain CDR1 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 7; a heavy chain CDR2 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 8; a heavy chain CDR3 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 9; and a light chain CDR1 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 10. a light chain CDR2 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 11, and a light chain CDR3 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 12 (c2); a heavy chain CDR1 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 13; a heavy chain CDR2 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 14; a heavy chain CDR3 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 15; a light chain CDR1 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 16; a light chain CDR2 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 17; and a light chain CDR3 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 18 (d2).a heavy chain CDR1 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 32; a heavy chain CDR2 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 33; a heavy chain CDR3 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 34; a light chain CDR1 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 35; a light chain CDR2 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 36; and a light chain CDR3 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 37. (e2) A heavy chain CDR1 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 38; a heavy chain CDR2 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 39; and a heavy chain CDR3 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 40. a light chain CDR1 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 41; a light chain CDR2 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 42; and a light chain CDR3 consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 43.
[0043] The anti-COPB2 antibody is preferably an antibody comprising any one of the above CDR sets (a) to (e), but may also be an antibody comprising any one of the above CDR sets (a2) to (e2). That is, the above explanation should be understood as meaning that the antigen-binding fragment of the anti-COPB2 antibody is preferably an antigen-binding fragment comprising any one of the above CDR sets (a) to (e), but may also be an antigen-binding fragment comprising any one of the above CDR sets (a2) to (e2). In the above CDR sets (a2) to (e2), the heavy chain CDR1 to CDR3 and the light chain CDR1 to CDR3 may be any one of the above CDR sets (a) to (e). In the above-mentioned sets of CDRs (a2) to (e2), if the set is not one of the above-mentioned sets of CDRs (a) to (e), the amino acid sequence of any of the CDRs may be an amino acid sequence having 80% or more identity to the amino acid sequences represented by SEQ ID NOs: 1 to 6, and there may be 1 to 6 CDRs having amino acid sequences having 80% or more identity.
[0044] When an anti-COPB2 antibody or antigen-binding fragment thereof has any of the CDR sets (a2) to (e2) above, the antibody or antigen-binding fragment thereof has or retains the ability to bind to COPB2 in any of the CDR sets.
[0045] As used herein, "having 80% or more identity" means that when the amino acid sequence before mutation and the amino acid sequence mutated from the amino acid sequence are aligned to maximize identity, the number of common amino acid residues is 80% or more of the number of amino acids in the amino acid sequence before mutation. The identity may be, for example, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more. The identity may also be 100%. A set of heavy chain CDR1 to CDR3 and light chain CDR1 to CDR3 consisting only of amino acid sequences that share 100% identity is a CDR set of any of (a) to (e) above.
[0046] In one aspect of this embodiment, the anti-COPB2 antibody or antigen-binding fragment thereof may be an anti-COPB2 antibody or antigen-binding fragment thereof comprising a heavy chain variable region and / or a light chain variable region of (f) to (j) below. The heavy chain variable regions and / or light chain variable regions of (f) to (j) below preferably have any of the CDR sets described above, and more preferably have any of the CDR sets described in (a) to (e) above. Taking (f) as an example (the same applies to (g) to (j)), the heavy chain variable region and / or light chain variable region of (f) means any of the heavy chain variable regions described in (f), any of the light chain variable regions described in (f), or any of the heavy chain variable regions described in (f) and any of the light chain variable regions described in (f). The anti-COPB2 antibody preferably comprises a heavy chain variable region and a light chain variable region of any of (f) to (j) below. In this case, for example, in the case of (f), it is more preferable that the antibody comprises any of the heavy chain variable regions of (f) and any of the light chain variable regions of (f). (f) a heavy chain variable region comprising the amino acid sequence represented by SEQ ID NO: 19; a heavy chain variable region comprising an amino acid sequence represented by SEQ ID NO: 19, which contains one to several amino acid additions, substitutions or deletions; or a heavy chain variable region comprising an amino acid sequence having 80% or more identity to the amino acid sequence represented by SEQ ID NO: 19, a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 20; a light chain variable region comprising an amino acid sequence represented by SEQ ID NO: 20, which contains one to several amino acid additions, substitutions or deletions; or a light chain variable region comprising an amino acid sequence having 80% or more identity to the amino acid sequence represented by SEQ ID NO: 20 (g) a heavy chain variable region comprising the amino acid sequence represented by SEQ ID NO: 21; a heavy chain variable region comprising an amino acid sequence represented by SEQ ID NO: 21, which contains one to several amino acid additions, substitutions or deletions; or a heavy chain variable region comprising an amino acid sequence having 80% or more identity to the amino acid sequence represented by SEQ ID NO: 21, a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 22;a light chain variable region comprising the amino acid sequence of SEQ ID NO: 22, but with one to several amino acid additions, substitutions or deletions; or a light chain variable region comprising an amino acid sequence having 80% or more identity to the amino acid sequence of SEQ ID NO: 22; (h) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 23; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 23, but with one to several amino acid additions, substitutions or deletions; or a heavy chain variable region comprising an amino acid sequence having 80% or more identity to the amino acid sequence of SEQ ID NO: 23; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 24; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 24, but with one to several amino acid additions, substitutions or deletions; or a light chain variable region comprising an amino acid sequence having 80% or more identity to the amino acid sequence of SEQ ID NO: 24; (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 44; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 44, but with one or more amino acid additions, substitutions or deletions; or a heavy chain variable region comprising an amino acid sequence having 80% or more identity to the amino acid sequence of SEQ ID NO: 44, a light chain variable region comprising the amino acid sequence of SEQ ID NO: 45; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 45, but with one or more amino acid additions, substitutions or deletions; or a light chain variable region comprising an amino acid sequence having 80% or more identity to the amino acid sequence of SEQ ID NO: 45. (j) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 46; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 46, but with one or more amino acid additions, substitutions or deletions; or a heavy chain variable region comprising an amino acid sequence having 80% or more identity to the amino acid sequence of SEQ ID NO: 46, a light chain variable region comprising the amino acid sequence of SEQ ID NO: 47; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 47, but with one or several amino acid additions, substitutions, or deletions;or a light chain variable region comprising an amino acid sequence having 80% or more identity to the amino acid sequence represented by SEQ ID NO: 47;
[0047] The heavy chain variable region and the light chain variable region each have a framework region (FR) in addition to CDRs. The amino acid sequence of the FR may be the same amino acid sequence derived from the FR of each variable region of each immunoglobulin, or may be a sequence containing a mutation in the amino acid sequence, or may be a partially modified sequence, such as by introducing a restriction enzyme recognition site into a portion of the amino acid sequence derived from the FR. In the amino acid sequences of the heavy chain variable region and / or the light chain variable region, amino acid mutations may be in a region other than the CDR, i.e., in the FR, from the viewpoint of having little effect on reactivity with antigens.
[0048] The anti-COPB2 antibody comprises the following set of CDRs: a heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 1; a heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 2; a heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 3; a light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 4; a light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 5; and a light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 6. The anti-COPB2 antibody may also comprise any one of the following heavy chain variable regions and / or any one of the following light chain variable regions. a heavy chain variable region comprising the amino acid sequence represented by SEQ ID NO: 19; a heavy chain variable region comprising an amino acid sequence comprising the amino acid sequence represented by SEQ ID NO: 19, but with one to several amino acid additions, substitutions or deletions; or a heavy chain variable region comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 19; a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 20; a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 20, but with one to several amino acid additions, substitutions or deletions; or a light chain variable region comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 20
[0049] The anti-COPB2 antibody comprises the following set of CDRs: a heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 7; a heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 8; a heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 9; a light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 10; a light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 11; and a light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 12. The anti-COPB2 antibody may also comprise any one of the following heavy chain variable regions and / or any one of the following light chain variable regions. a heavy chain variable region comprising the amino acid sequence represented by SEQ ID NO: 21; a heavy chain variable region comprising the amino acid sequence represented by SEQ ID NO: 21, but with one to several amino acid additions, substitutions, or deletions; or a heavy chain variable region comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 21; a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 22; a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 22, but with one to several amino acid additions, substitutions, or deletions; or a light chain variable region comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 22
[0050] The anti-COPB2 antibody comprises the following set of CDRs: a heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 13; a heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 14; a heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 15; a light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 16; a light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 17; and a light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 18. The anti-COPB2 antibody may also comprise any one of the following heavy chain variable regions and / or any one of the following light chain variable regions. a heavy chain variable region comprising the amino acid sequence represented by SEQ ID NO: 23; a heavy chain variable region comprising an amino acid sequence comprising the amino acid sequence represented by SEQ ID NO: 23, but with one to several amino acid additions, substitutions or deletions; or a heavy chain variable region comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 23; a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 24; a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 24, but with one to several amino acid additions, substitutions or deletions; or a light chain variable region comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 24
[0051] The anti-COPB2 antibody comprises the following set of CDRs: a heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 32; a heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 33; a heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 34; a light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 35; a light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 36; and a light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 37. The anti-COPB2 antibody may also comprise any one of the following heavy chain variable regions and / or any one of the following light chain variable regions. a heavy chain variable region comprising the amino acid sequence represented by SEQ ID NO: 44; a heavy chain variable region comprising an amino acid sequence comprising the amino acid sequence represented by SEQ ID NO: 44, but with one or more amino acid additions, substitutions or deletions; or a heavy chain variable region comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 44; a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 45; a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 45, but with one or more amino acid additions, substitutions or deletions; or a light chain variable region comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 45
[0052] The anti-COPB2 antibody comprises the following set of CDRs: a heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 38; a heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 39; a heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 40; a light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 41; a light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 42; and a light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 43. The anti-COPB2 antibody may also comprise any one of the following heavy chain variable regions and / or any one of the following light chain variable regions. a heavy chain variable region comprising the amino acid sequence represented by SEQ ID NO: 46; a heavy chain variable region comprising an amino acid sequence comprising the amino acid sequence represented by SEQ ID NO: 46, but with one or more amino acid additions, substitutions or deletions; or a heavy chain variable region comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 46; a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 47; a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 47, but with one or more amino acid additions, substitutions or deletions; or a light chain variable region comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 47
[0053] In an anti-COPB2 antibody, regions other than the CDRs when CDRs are defined, and regions other than the variable regions when heavy and / or light chain variable regions are defined, may be selected from regions of conventional antibodies, as long as the anti-COPB2 antibody has the ability to bind to COPB2. Furthermore, the heavy and light chain variable regions of an anti-COPB2 antibody may have amino acid sequences derived from the amino acid sequences represented by SEQ ID NOs: 19 to 24 and 44 to 47, from which the amino acids constituting the signal sequence have been deleted. That is, the anti-COPB2 antibody may comprise a heavy chain variable region comprising an amino acid sequence derived from the amino acid sequence represented by any one of SEQ ID NOs: 19, 21, 23, 44, and 46, from which the amino acids constituting the signal sequence have been deleted, and / or a light chain variable region comprising an amino acid sequence derived from the amino acid sequence represented by any one of SEQ ID NOs: 20, 22, 24, 45, and 47, from which the amino acids constituting the signal sequence have been deleted. A heavy chain variable region or light chain variable region comprising an amino acid sequence containing one to several amino acid additions, substitutions, or deletions may also be a heavy chain variable region or light chain variable region comprising an amino acid sequence containing one to several amino acid additions, substitutions, or deletions in an amino acid sequence obtained by deleting the amino acids constituting the signal sequence from the amino acid sequence represented by any of SEQ ID NOs: 19 to 24 and 44 to 47. Furthermore, a heavy chain variable region or light chain variable region comprising an amino acid sequence with 80% or more identity may also be a heavy chain variable region or light chain variable region comprising an amino acid sequence with 80% or more identity to an amino acid sequence obtained by deleting the amino acids constituting the signal sequence from the amino acid sequence represented by any of SEQ ID NOs: 19 to 24 and 44 to 47. The signal sequence corresponds to approximately 20 amino acids from the N-terminal amino acid in the heavy chain variable region or light chain variable region.
[0054] The amino acid sequences corresponding to the signal sequences are as follows: SEQ ID NO: 19: positions 1 to 28 SEQ ID NO: 20: positions 1 to 36 SEQ ID NO: 21: positions 1 to 28 SEQ ID NO: 22: positions 1 to 22 SEQ ID NO: 23: positions 1 to 19 SEQ ID NO: 24: positions 1 to 19 SEQ ID NO: 44: positions 1 to 19 SEQ ID NO: 45: positions 1 to 20 SEQ ID NO: 46: positions 1 to 19 SEQ ID NO: 47: positions 1 to 22 Therefore, with regard to the anti-COPB2 antibody or antigen-binding fragment thereof comprising the heavy chain variable region and / or light chain variable region of (f) to (j) above, an antibody or antigen-binding fragment thereof that does not contain a signal sequence may also be an anti-COPB2 antibody or antigen-binding fragment thereof comprising the heavy chain variable region and / or light chain variable region of (f1) to (j1) below. (f1) a heavy chain variable region comprising the amino acid sequence represented by positions 29 to 145 of SEQ ID NO: 19 (SEQ ID NO: 25); a heavy chain variable region comprising an amino acid sequence comprising the amino acid sequence represented by positions 29 to 145 of SEQ ID NO: 19, but with one or several amino acid additions, substitutions, or deletions; or a heavy chain variable region comprising an amino acid sequence having 80% or more identity to the amino acid sequence represented by positions 29 to 145 of SEQ ID NO: 19, a light chain variable region comprising the amino acid sequence represented by positions 37 to 143 of SEQ ID NO: 20 (SEQ ID NO: 26); a light chain variable region comprising the amino acid sequence represented by positions 37 to 143 of SEQ ID NO: 20, but with one or several amino acid additions, substitutions, or deletions; or a light chain variable region comprising an amino acid sequence having 80% or more identity to the amino acid sequence represented by positions 37 to 143 of SEQ ID NO: 20 (g1) a heavy chain variable region comprising the amino acid sequence represented by positions 29 to 145 of SEQ ID NO: 21 (SEQ ID NO: 27); a heavy chain variable region comprising an amino acid sequence containing one to several amino acid additions, substitutions, or deletions in the amino acid sequence represented by positions 29 to 145 of SEQ ID NO: 21; or a heavy chain variable region comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by positions 29 to 145 of SEQ ID NO: 21; a light chain variable region comprising an amino acid sequence represented by positions 23 to 129 of SEQ ID NO: 22 (SEQ ID NO: 28);a light chain variable region comprising an amino acid sequence represented by positions 23 to 129 of SEQ ID NO: 22, with one to several amino acid additions, substitutions or deletions; or a light chain variable region comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by positions 23 to 129 of SEQ ID NO: 22. (h1) a heavy chain variable region comprising an amino acid sequence represented by positions 20 to 134 of SEQ ID NO: 23 (SEQ ID NO: 29); a heavy chain variable region comprising an amino acid sequence represented by positions 20 to 134 of SEQ ID NO: 23, with one to several amino acid additions, substitutions or deletions; or a heavy chain variable region comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by positions 20 to 134 of SEQ ID NO: 23, a light chain variable region comprising an amino acid sequence represented by positions 20 to 131 of SEQ ID NO: 24 (SEQ ID NO: 30); a light chain variable region comprising an amino acid sequence represented by positions 20 to 131 of SEQ ID NO: 24, with one to several amino acid additions, substitutions or deletions; or a light chain variable region comprising an amino acid sequence having 80% or more identity to the amino acid sequence represented by positions 20 to 131 of SEQ ID NO: 24. (i1) a heavy chain variable region comprising an amino acid sequence represented by positions 20 to 146 of SEQ ID NO: 44 (SEQ ID NO: 48); a heavy chain variable region comprising an amino acid sequence represented by positions 20 to 146 of SEQ ID NO: 44, with one to several amino acid additions, substitutions or deletions; or a heavy chain variable region comprising an amino acid sequence having 80% or more identity to the amino acid sequence represented by positions 20 to 146 of SEQ ID NO: 44, a light chain variable region comprising an amino acid sequence represented by positions 21 to 132 of SEQ ID NO: 45 (SEQ ID NO: 49); a light chain variable region comprising an amino acid sequence represented by positions 21 to 132 of SEQ ID NO: 45, with one to several amino acid additions, substitutions, or deletions; or a light chain variable region comprising an amino acid sequence having 80% or more identity to the amino acid sequence represented by positions 21 to 132 of SEQ ID NO: 45. (j1) a heavy chain variable region comprising an amino acid sequence represented by positions 20 to 144 of SEQ ID NO: 46 (SEQ ID NO: 50); a heavy chain variable region comprising an amino acid sequence represented by positions 20 to 144 of SEQ ID NO: 46, with one to several amino acid additions, substitutions, or deletions;or a heavy chain variable region comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by positions 20 to 144 of SEQ ID NO: 46; a light chain variable region comprising an amino acid sequence represented by positions 23 to 129 of SEQ ID NO: 47 (SEQ ID NO: 51); a light chain variable region comprising an amino acid sequence comprising the amino acid sequence represented by positions 23 to 129 of SEQ ID NO: 47, but with one to several amino acid additions, substitutions, or deletions; or a light chain variable region comprising an amino acid sequence having 80% or more identity with the amino acid sequence represented by positions 23 to 129 of SEQ ID NO: 47;
[0055] The anti-COPB2 antibody or antigen-binding fragment thereof comprising the heavy chain variable region and / or light chain variable region (f1) to (j1) above is preferably an antibody or antigen-binding fragment thereof comprising any of the CDR sets (a) to (e), (a1) to (e1), or (a2) to (e2) above. That is, when an anti-COPB2 antibody or antigen-binding fragment thereof comprises the heavy chain variable region and / or light chain variable region of (f1) to (j1) above, the anti-COPB2 antibody or antigen-binding fragment thereof comprises the heavy chain variable region and / or light chain variable region of (f1), it preferably comprises any one of the CDR sets of (a), (a1) or (a2), and more preferably comprises the CDR set of (a); when an anti-COPB2 antibody or antigen-binding fragment thereof comprises the heavy chain variable region and / or light chain variable region of (g1), it preferably comprises any one of the CDR sets of (b), (b1) or (b2), and more preferably comprises the CDR set of (b); when an anti-COPB2 antibody or antigen-binding fragment thereof comprises the heavy chain variable region and / or light chain variable region of (h1), it preferably comprises any one of the CDR sets of (c), (c1) or (c2), and more preferably comprises the CDR set of (c); In the case of an anti-COPB2 antibody or antigen-binding fragment thereof comprising the heavy chain variable region and / or light chain variable region of (i1), it preferably comprises any one of the CDR sets of (d), (d1) or (d2), more preferably the CDR set of (d); and in the case of an anti-COPB2 antibody or antigen-binding fragment thereof comprising the heavy chain variable region and / or light chain variable region of (j1), it preferably comprises any one of the CDR sets of (e), (e1) or (e2), more preferably the CDR set of (e).
[0056] The antibody or antigen-binding fragment thereof may comprise any of the CDR sets (a) to (e), which comprise the heavy chain variable regions and / or light chain variable regions (f1) to (j1) above. The descriptions of the heavy chain variable regions and / or light chain variable regions (f) to (j) are understood to also refer to the heavy chain variable regions and / or light chain variable regions (f1) to (j1). The following descriptions in this specification regarding nucleic acids, expression vectors, transformants, production methods, kits, etc. are also understood to also refer to the heavy chain variable regions and / or light chain variable regions (f1) to (j1), as well as the heavy chain variable regions and / or light chain variable regions (f) to (j).
[0057] In one aspect of this embodiment, the anti-COPB2 antibody or antigen-binding fragment thereof is not particularly limited as long as it is derived from an antibody against COPB2, and may be a commercially available anti-COPB2 antibody or antigen-binding fragment thereof. The anti-COPB2 antibody is not particularly limited as long as it is generally available. Examples of the anti-COPB2 antibody include an anti-COPB2 monoclonal antibody manufactured by Novus Biologicals (product name: COPB2 Antibody (M3A5), product code: NB600-102, etc.), an anti-COPB2 polyclonal antibody manufactured by Bethyl Laboratories (product name: COPB2 Polyclonal Antibody, catalog numbers: Cat# A304-522A, Cat# A304-523A, Cat# A304-522A-M, Cat# A304-523A-M, etc.), and an anti-COPB2 polyclonal antibody manufactured by Invitrogen (product name: COPB2 Polyclonal Antibody, catalog numbers: Cat# A304-522A, Cat# A304-523A, Cat# A304-523A-M, etc.). Antibody, catalog numbers: Catalog # PA5-77106, # PA5-96557, # PA5-49113, # PA5-57852, # PA5-66144, etc.), anti-COPB2 antibody manufactured by AssayGenie (product name: Anti-COPB2 Antibody, catalog numbers: PACO44494, CAB7036, etc.), anti-COPB2 polyclonal antibody manufactured by Solarbio (product name: Anti-COPB2 Polyclonal Antibody, catalog number: K110122P-SAlexa Fluor 633, etc.), anti-COPB2 polyclonal antibody manufactured by Abcam (product name: Anti-COPB2 Anti-COPB2 antibodies can also be obtained as commercially available anti-COPB2 antibodies (antibody, product codes: ab229639, ab2915, ab192924, etc.), or as anti-COPB2 antibodies manufactured by Atlas Antibodies (product name: Anti-COPB2 antibody produced in rabbit, product numbers: HPA036867, HPA058180, etc.). Furthermore, the anti-COPB2 antibody or antigen-binding fragment thereof may comprise an amino acid sequence that is 80% or more identical to the amino acid sequence of a commercially available anti-COPB2 antibody.
[0058] In one aspect of this embodiment, the antigen of the anti-COPB2 antibody or antigen-binding fragment thereof is not particularly limited as long as it is derived from the amino acid sequence of COPB2. The amino acid sequence of the antigen is not particularly limited, but is, for example, as follows: Full-length amino acid sequence of human COPB2 (SEQ ID NO: 31) Amino acid sequence corresponding to positions 286 to 380 in the amino acid sequence of human COPB2 Amino acid sequence corresponding to positions 494 to 511 in the amino acid sequence of human COPB2 Amino acid sequence corresponding to positions 650 to 906 in the amino acid sequence of human COPB2 Amino acid sequence corresponding to positions 657 to 906 in the amino acid sequence of human COPB2 Amino acid sequence corresponding to positions 707 to 786 in the amino acid sequence of human COPB2 Amino acid sequence corresponding to positions 800 to 850 in the amino acid sequence of human COPB2 Amino acid sequence corresponding to positions 814 to 843 in the amino acid sequence of human COPB2 Amino acid sequence corresponding to positions 850 to 906 in the amino acid sequence of human COPB2 Amino acid sequence corresponding to positions 856 to 906 in the amino acid sequence of human COPB2 Among these, the amino acid sequence of the antigen is not particularly limited, but is preferably an amino acid sequence consisting of 25 to 257 consecutive amino acid residues selected from the amino acid sequence corresponding to positions 650 to 906 of the amino acid sequence of human COPB2, and more preferably the following amino acid sequences: The amino acid sequence corresponding to positions 650 to 906 of the amino acid sequence of human COPB2 The amino acid sequence corresponding to positions 850 to 906 of the amino acid sequence of human COPB2 The amino acid sequence corresponding to positions 856 to 906 of the amino acid sequence of human COPB2
[0059] The anti-COPB2 antibody or antigen-binding fragment thereof may be an antibody against an antigen having the amino acid sequence represented by SEQ ID NO: 31, or an antigen-binding fragment thereof. The anti-COPB2 antibody or antigen-binding fragment thereof may be an antibody against an antigen having the amino acid sequence represented by SEQ ID NO: 31, the amino acid sequence from positions 286 to 380, the amino acid sequence from positions 494 to 511, the amino acid sequence from positions 650 to 906, the amino acid sequence from positions 657 to 906, the amino acid sequence from positions 707 to 786, the amino acid sequence from positions 800 to 850, the amino acid sequence from positions 814 to 843, the amino acid sequence from positions 850 to 906, or the amino acid sequence from positions 856 to 906, or an antigen-binding antibody ... The antibody may be an antibody against an antigen having the amino acid sequence of amino acids 650 to 906, the amino acid sequence of amino acids 657 to 906, the amino acid sequence of amino acids 707 to 786, the amino acid sequence of amino acids 800 to 850, the amino acid sequence of amino acids 814 to 843, the amino acid sequence of amino acids 850 to 906, or the amino acid sequence of amino acids 856 to 906, or an antigen-binding antibody thereof. The antibody may be an antibody against an antigen having the amino acid sequence of amino acids 650 to 906, the amino acid sequence of amino acids 850 to 843, or the amino acid sequence of amino acids 856 to 906 in the amino acid sequence represented by SEQ ID NO: 31, or an antigen-binding fragment thereof.
[0060] (Method for Producing Anti-COPB2 Antibody or Antigen-Binding Fragment Thereof) The method for producing an anti-COPB2 antibody or an antigen-binding fragment thereof is not particularly limited, but in the case of a monoclonal antibody, it may be a method in which antibody-producing cells are isolated from a non-human mammal immunized with COPB2 or a fragment thereof, and these are fused with myeloma cells or the like to produce hybridomas, and the antibodies produced by these hybridomas are purified. Furthermore, polyclonal antibodies may be obtained from the serum of an animal immunized with COPB2 or a fragment thereof.
[0061] When an anti-COPB2 antibody or an antigen-binding fragment thereof is produced by genetic recombination, for example, a suitable host cell may be transformed with an expression vector containing a nucleic acid encoding the anti-COPB2 antibody or the antigen-binding fragment thereof, and the resulting transformant may be cultured under appropriate conditions to express the antibody or antigen-binding fragment, which may then be isolated and purified by known methods or methods equivalent thereto.
[0062] The method for isolating and purifying the antibody or antigen-binding fragment is not particularly limited, and examples include column purification using an affinity column using protein A or other chromatography columns, filter filtration, ultrafiltration, salting out, dialysis, and the like, and these may be combined as appropriate.
[0063] When an anti-COPB2 antibody has CDRs consisting of amino acid sequences in which amino acids have been added, substituted, or deleted from the amino acid sequences of heavy chain CDR1 to 3 and light chain CDR1 to 3, or when the anti-COPB2 antibody has CDRs consisting of amino acid sequences in which the amino acid sequences of heavy chain CDR1 to 3 and light chain CDR1 to 3 have 80% or more identity, the anti-COPB2 antibody may be prepared using known methods such as site-directed mutagenesis, random mutagenesis, chain shuffling, and CDR walking.
[0064] It is well known to those skilled in the art that antibodies or antigen-binding fragments thereof having a more affinity-matured set of CDRs can be obtained by displaying antibodies or antigen-binding fragments thereof having various mutations in the CDRs on the surface of phages using phage display methods and screening using antigens (e.g., Wu et al., PNAS, 95:6037-6042 (1998); Schier, R. et al., J. Mol. Biol. 263:551-567 (1996); Schier, R. et al., J. Mol. Biol. 255:28-43 (1996); Yang, W.P. et al., J. Mol. Biol., 254:392-403 (1995)). Therefore, anti-COPB2 antibodies may be produced by this method.
[0065] Chimeric, humanized, and human antibodies may be produced by known methods or methods equivalent thereto. They may also be produced using genes obtained by cloning an antibody gene from the mRNA of a hybridoma that produces an antibody from a non-human animal and linking it to a part of a human antibody gene using genetic recombination techniques. The gene for the anti-COPB2 antibody may be determined according to the amino acid sequences of the CDRs and the variable regions described above in (a) to (j).
[0066] There are no particular limitations on the method for producing chimeric antibodies. For example, chimeric antibodies may be produced using nucleic acids obtained by replacing the heavy chain variable region (VH) and light chain variable region (VL) of (f) to (j) above with sequences derived from a human antibody by genetic recombination. Alternatively, the heavy and light chain constant regions of human IgG1 may be cloned, and the heavy chain variable region (VH) and light chain variable region (VL) of (f) to (j) above may be linked to the human antibody-derived constant regions by PCR using the overlapping hanging method. The amplified DNA may then be inserted into an appropriate vector, which may then be transformed to obtain a chimeric antibody.
[0067] To prepare a humanized antibody, the variable region of a human antibody is cloned and then modified by site-directed mutagenesis using the megaprimer method to create the CDR nucleotide sequence of an anti-COPB2 antibody. If humanization of the amino acid sequence constituting the framework region results in a loss of specific binding to the antigen, some amino acids in the framework may be converted from human to rat types.
[0068] CDRs consisting of an amino acid sequence in which one or more amino acids have been deleted, substituted, or added in the amino acid sequence of the original CDR, or CDRs consisting of an amino acid sequence that is 80% or more identical to the original sequence, may be prepared using known methods such as site-directed mutagenesis, random mutagenesis, chain shuffling, and CDR walking.
[0069] An antigen-binding fragment of an anti-COPB2 antibody may be expressed by the above-described method using a nucleic acid encoding the fragment, or the full-length antibody may be obtained and then fragmented by treating it with an enzyme such as papain or pepsin.
[0070] The anti-COPB2 antibody or antigen-binding fragment thereof obtained by the above production method can be confirmed to be an anti-COPB2 antibody, for example, by the ability to detect COPB2 protein in a sample by immunoassay using the anti-COPB2 antibody or antigen-binding fragment thereof. Immunoassays for detecting target proteins by immunoassay are well known in the art. Reagents required for each immunoassay are also well known, and immunological detection of COPB2 protein may be performed using an anti-COPB2 antibody or an antigen-binding fragment thereof as the antibody used in the immunoassay and a conventional immunoassay kit. The immunoassay is not particularly limited, but preferred examples include immunohistochemistry (IHC), immunofluorescence (IF), flow cytometry, enzyme-linked immunosorbent assay (ELISA), and immunoblotting.
[0071] (Pharmaceutical Composition) The pharmaceutical composition for treating or preventing cancer of this embodiment contains an antibody against COPB2 or an antigen-binding fragment thereof. Here, the antibody against COPB2 or an antigen-binding fragment thereof may be the same as those described above.
[0072] As used herein, the term "treatment or prevention" refers to therapeutic and / or prophylactic treatment. The term "therapeutic or prophylactic treatment" is art-recognized and may include administration of a pharmaceutical composition to a subject. Therapeutic treatment may refer to administration after the onset of an undesirable condition (e.g., a disease or other undesirable condition in a subject) and may be intended to attenuate, suppress, ameliorate, alleviate, or stabilize an existing undesirable condition or its side effects. It may also include attenuation of any direct or indirect pathological effects of the disease, and prevention of metastasis. It may also refer to treatment to delay the onset of the disease or slow the progression of the disease. Prophylactic treatment may refer to administration prior to clinical observation of the undesirable condition and may be intended to inhibit and / or prevent the recurrence of the undesirable condition.
[0073] As used herein, the term "pharmaceutical composition" may refer to a pharmaceutical formulation or preparation commonly used in the art, which contains an active ingredient and additives (such as pharmaceutically acceptable ingredients). In this embodiment, the pharmaceutical composition contains at least an antibody against COPB2 or an antigen-binding fragment thereof as an active ingredient.
[0074] One aspect of this embodiment is a pharmaceutical composition for treating cancer. The treatment of cancer is not particularly limited, but may mean that the number of cancer cells in a subject is reduced, cancer cells are eliminated, cancer cell proliferation is inhibited, tumor size is reduced, cancer cell infiltration into peripheral organs is inhibited, cancer cell metastasis is inhibited, or various symptoms caused by cancer are improved, by single-agent administration or combination therapy of the pharmaceutical composition of this embodiment, and preferably means that cancer cells are eliminated or cancer cell metastasis is inhibited.
[0075] One aspect of this embodiment is a pharmaceutical composition for preventing cancer. Prevention of cancer is not particularly limited, and may mean suppressing the recurrence of cancer, and preferably means preventing an increase in the number of cancer cells due to the re-proliferation of reduced cancer cells, preventing the re-proliferation of cancer cells whose proliferation has been suppressed, or preventing a re-increase in the size of a reduced tumor.
[0076] As used herein, the term "cancer" refers to a physiological condition in mammals that is typically characterized by unregulated cell growth / proliferation. The terms "cancer," "carcinoma," "tumor," "neoplasm," and the like are indistinguishable and are interchangeable.
[0077] The cancer is not particularly limited, but examples include primary tumors, advanced cancers, recurrent cancers, metastatic cancers, or combinations thereof, and it is more preferable to use the drug in the treatment or prevention of primary tumors.
[0078] As used herein, the term "recurrence" means the recurrence of cancer after a period in which the cancer was undetectable, the re-growth of cancer that has shrunk due to treatment, or the appearance of the same cancer in another location. For purposes of this specification, the term "metastasis" means the migration of cancer cells from the site of initial development to another organ or tissue via blood vessels or lymphatics, where they multiply.
[0079] The cancer may be cancer occurring in any organ or tissue, but is preferably cancer occurring in an organ or tissue in which COPB2 is distributed. The cancer is not particularly limited, but examples include cancer occurring in the brain, eye, endocrine tissue, respiratory system, digestive tract, liver, gallbladder, pancreas, kidney, bladder, reproductive tissue, muscle tissue, connective tissue, soft tissue, skin, bone marrow, lymphatic tissue, etc. Furthermore, the cancer may be either an epithelial malignant tumor or a non-epithelial malignant tumor. Specific cancers include, but are not limited to, thyroid cancer, adrenocortical carcinoma (ACC), lung cancer (e.g., small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma (LUAD), squamous cell carcinoma of the lung, etc.), gastrointestinal cancer (e.g., esophageal cancer, gastric cancer, colon cancer, rectal adenocarcinoma (READ)), etc.), bile duct cancer (CHOL), liver cancer, hepatocellular carcinoma, hepatoma, pancreatic cancer, kidney cancer (e.g., kidney chromophobe (KICH), papillary cell renal carcinoma (KIRP)), etc.), bladder cancer, peritoneal cancer, salivary gland cancer, skin cancer (e.g., cutaneous melanoma (SKCM)), squamous cell carcinoma, multiple myeloma, glioma, brain tumor (e.g., brain low-grade malignant potential Neuroglioma (LGG), glioblastoma multiforme (GBM), etc.), pheochromocytoma, paracancerous glioma (PCPG), uterine cancer (e.g., endometrial cancer, uterine cancer, cervical cancer, uterine carcinosarcoma (UCS), etc.), ovarian cancer (e.g., ovarian serous cystadenocarcinoma (OV)), breast cancer (e.g., breast adenocarcinoma, invasive breast cancer (BRCA)), prostate cancer, testicular cancer (e.g., testicular germ cell tumor (TGCT)), vulvar cancer, thymoma (THYM), leukemia (e.g., AML (acute myeloid leukemia), CML (chronic myeloid leukemia), etc.), malignant lymphoma, ALL (acute lymphocytic leukemia), CLL (chronic lymphocytic leukemia), Hodgkin's disease These include Hodgkin's lymphoma, non-Hodgkin's lymphoma, lymphoid neoplasms such as diffuse large B-cell lymphoma (DLBC) and other lymphoproliferative disorders.Among these, the pharmaceutical composition of the present embodiment is preferably used for the treatment or prevention of one or more cancers selected from the group consisting of breast cancer, glioma, gastrointestinal cancer, hepatocellular carcinoma, liver cancer, prostate cancer, lung cancer, and pancreatic cancer, and more preferably for the treatment or prevention of one or more cancers selected from the group consisting of breast cancer, liver cancer, gastric cancer, colon cancer, hepatocellular carcinoma, prostate cancer, lung cancer, and pancreatic cancer.
[0080] The pharmaceutical composition of this embodiment comprises an anti-COPB2 antibody or an antigen-binding fragment thereof, and may further comprise a pharmaceutically acceptable carrier and / or additive. The proportion of the carrier or additive may be appropriately determined based on the range commonly used in the pharmaceutical field. Examples of the carrier include, but are not limited to, water, physiological saline, other aqueous solvents, and aqueous or oily bases. Examples of the additive include, but are not limited to, excipients, binders, pH adjusters, disintegrants, absorption enhancers, lubricants, colorants, flavorings, and fragrances.
[0081] The formulation form of the pharmaceutical composition is not particularly limited, and examples thereof include oral preparations such as tablets, coated tablets, pills, powders, granules, capsules, liquids, suspensions, and emulsions, and parenteral preparations such as injections, infusions, suppositories, ointments, and patches.
[0082] The method of administration of the pharmaceutical composition is not particularly limited, but is preferably administered parenterally as an injection or infusion, for example, intravenously, intramuscularly, intradermally, intraperitoneally, subcutaneously, or topically, with topical administration being more preferred. An injection or infusion containing an anti-COPB2 antibody or an antigen-binding fragment thereof can be used as a solution, suspension, or emulsion. Examples of solvents include distilled water for injection, physiological saline, glucose solution, and isotonic solutions (e.g., solutions of sodium chloride, potassium chloride, glycerin, mannitol, sorbitol, boric acid, borax, propylene glycol, etc.). These solvents may be used alone or in combination of two or more.
[0083] Furthermore, the injection or infusion solution may contain additives such as stabilizers, solubilizers, suspending agents, emulsifiers, soothing agents, buffers, preservatives, antiseptics, and pH adjusters. Stabilizers include, but are not limited to, albumin, globulin, gelatin, mannitol, glucose, dextran, ethylene glycol, propylene glycol, ascorbic acid, sodium bisulfite, sodium thiosulfate, sodium EDTA, sodium citrate, and dibutylhydroxytoluene. Solubilizers include, but are not limited to, alcohols (e.g., ethanol), polyalcohols (e.g., propylene glycol, polyethylene glycol), and nonionic surfactants (e.g., Polysorbate 80 (registered trademark), HCO-50, and the like). Suspending agents include, but are not limited to, glycerin monostearate, aluminum monostearate, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, and sodium lauryl sulfate. Examples of emulsifiers include, but are not limited to, gum arabic, sodium alginate, tragacanth, etc. Examples of soothing agents include, but are not limited to, benzyl alcohol, chlorobutanol, sorbitol, etc. Examples of buffers include, but are not limited to, phosphate buffer, acetate buffer, borate buffer, carbonate buffer, citrate buffer, Tris buffer, etc. Examples of preservatives include, but are not limited to, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, chlorobutanol, benzyl alcohol, benzalkonium chloride, sodium dehydroacetate, sodium edetate, boric acid, borax, etc. Examples of antiseptics include, but are not limited to, benzalkonium chloride, parahydroxybenzoic acid, chlorobutanol, etc. Examples of pH adjusters include, but are not limited to, hydrochloric acid, sodium hydroxide, phosphoric acid, acetic acid, etc.
[0084] The dosage and administration interval of the active ingredient of the pharmaceutical composition can be appropriately selected depending on the subject to be administered, the administration route, the disease, and the subject's age, weight, and symptoms. For example, in the case of oral administration, the dosage of the active ingredient for an adult is, but is not particularly limited to, 0.01 mg to 10 g, 100 mg to 6 g, or 50 mg to 500 mg per day. The administration interval of the pharmaceutical composition may be such that the daily dosage is administered once a day or in divided doses.
[0085] The subject to which the pharmaceutical composition is administered is a mammal. Mammals include, but are not limited to, humans, non-human primates, domestic animals, laboratory animals, and livestock, with humans being preferred.
[0086] The pharmaceutical composition of the present embodiment may be administered in combination with one or more other agents, including, but not limited to, other therapeutic agents such as immunomodulators, cytostatic agents, inhibitors of cell adhesion, cytotoxic agents, activators of cell apoptosis, or agents that increase the sensitivity of cells to apoptosis-inducing factors, anti-cancer agents such as microtubule-disrupting agents, antimetabolites, topoisomerase inhibitors, DNA intercalators, alkylating agents, hormone therapy, kinase inhibitors, receptor antagonists, activators of tumor cell apoptosis, or anti-angiogenic agents.
[0087] In the combined administration, the pharmaceutical composition of this embodiment and the other agent may be administered at different times. When administered simultaneously, the two or more active ingredients may be in the same formulation or may be administered as separate formulations. When administered at different times, the two or more active ingredients may be administered according to the desired administration regimen. The dosage and administration interval of the other active ingredient may be in accordance with the predetermined administration regimen.
[0088] Some examples of the above-described embodiments of the present invention will be described below. The present invention will be specifically explained below using examples, but the present invention is not limited to these examples.
[0089] 1. Preparation of antigen protein. A cDNA encoding 255 amino acid residues corresponding to the 650th glutamine to the 906th aspartic acid in the amino acid sequence of human COPB2 was synthesized with a 6xHis tag attached downstream and cloned into the expression vector pcDNA5 / TO (ThermoFisher Scientific). This plasmid was transfected into Expi293 cells (ThermoFisher Scientific) to express human COPB2 antigen protein. Transfection was performed using Expi293fectamine (ThermoFisher Scientific) according to the method described in the package insert. Six days after transfection, the culture medium and cells were harvested, and cell extracts were prepared from the cells using RIPA (Invitrogen). 10 μL of the culture medium and 10 μg of the cell extract were subjected to SDS-PAGE under reducing conditions, and the expression of COPB2 (650-906) was confirmed by Western blotting using an anti-His tag antibody (Proteintech). As a result, the expression of COPB2 (650-906) was confirmed both in the culture medium and in the cells, but it was confirmed that it was expressed and accumulated more in the cells.
[0090] COPB2 (650-906) protein was purified from the culture medium and cells of transfected Expi293 cells using TALON resin (Clontech). A total of 524 μg of purified COPB2 (650-906) protein was obtained from the culture medium and cells after two transfection experiments.
[0091] 2. Production of Monoclonal Antibodies Three A / Jackson mice and three Balb / c mice were immunized with purified human COPB2 (650-906) protein. Each mouse was administered 50 μg intraperitoneally and 50 μg subcutaneously in the neck twice every three weeks. After the second immunization, blood samples were collected and the antibody titer against the antigen protein was measured. The principle of the measurement method is shown in Figure 1.
[0092] As a result, all A / Jackson mice immunized with human COPB2 protein showed high antibody titers of 800,000 counts or more, whereas Balb / c mice showed antibody titers of 200,000 counts or less (Figure 2).
[0093] One A / Jackson mouse (A / J#3) that showed high antibody titers after two immunizations with purified human COPB2 protein was administered the antigen protein as a final booster. Four days later, the spleen was removed to prepare splenocytes, which were then fused with myeloma cells (P3U1). The hybridomas were seeded into ten 96-well plates, and the culture supernatants in a total of 928 wells were assayed for antibody titers against the immunogen, human COPB2 protein, revealing five positive samples. The cells contained in these five positive sample wells were further cloned twice by limiting dilution. As a result, two hybridoma clones were established as cell lines producing antibodies highly reactive with COPB2 protein (clones #A3-3G10 and #A3-8C9).
[0094] Furthermore, splenocytes were prepared from a mouse (A / J#2 mouse) that showed a high antibody titer after the third immunization, and cell fusion was similarly performed. Screening of 768 hybridoma samples was performed. As a result, two positive samples were detected, and each was further cloned twice by limiting dilution (clones #A2-7C6 and #A2-7D11). As a result, a total of four anti-COPB2 monoclonal antibody clones were produced.
[0095] 3. Western Blot Study The antibodies of the four clones were examined to determine whether they could detect COPB2 protein in human cells and mouse cells by Western blotting. Specifically, 10 μg of cell extract prepared from human HEK293 cells using RIPA lysis solution (Santa Cruz Biotechnology) and 5 and 10 μg of tissue extract prepared from mouse liver using T-PER lysis solution (ThermoFisher Scientific) were subjected to SDS-PAGE under reducing conditions and then transferred to an Immobilon-P membrane (Merck Millipore). Blocking was performed for 1 hour at room temperature using TBS-T (0.05 M Tris-HCl, 0.15 M NaCl, 0.05% Tween 20, pH 7.6) containing 3% skim milk, and the membrane was then reacted overnight at 4°C with a solution of each antibody dissolved in TBS-T containing 3% skim milk at a concentration of 1 μg / mL. After the incubation, each membrane was washed three times with TBS-T for 10 minutes each. It was then incubated with a 1:1000 dilution of HRP-labeled rabbit anti-mouse IgG polyclonal antibody (Dako) in TBS-T containing 3% skim milk for 2 hours at 4°C. After washing three times with TBS-T for 10 minutes each, the membrane was detected using ChemiLumiOne Super (Nacalai Tesque) (Figure 3). The results indicated that all antibodies strongly reacted with human COPB2, and clones #A2-7C6 and #A2-7D11 also cross-reacted with mouse COPB2. Clone #A3-3G10 weakly cross-reacted with mouse COPB2, while clone #A3-8C9 showed no cross-reaction with mouse COPB2.
[0096] 4. Structural Analysis of Anti-COPB2 Antibodies Structural analysis of the heavy chain variable region and light chain variable region of the anti-COPB2 monoclonal antibodies A2-7C6, A2-7D11, and A3-8C9 was performed using a bioinformatics analysis system from Repertoire Genesis Inc. The amino acid sequences of the heavy chain CDR1 to 3 and light chain CDR1 to 3, as well as the heavy chain variable region and light chain variable region of the anti-COPB2 monoclonal antibodies A2-7C6, A2-7D11, and A3-8C9, are shown in Figures 4 to 6.
[0097] 5. Production of human monoclonal antibodies a: Antibody induction by immunization Five TC-mAb mice (Trans Chromosomics, Inc.) (individual numbers: 7337, 7366, 7397, 7412, 7484) were immunized with purified human COPB2 (650-906) protein. Immunizations were administered at multiple sites on each mouse, with two or more doses administered over a three-week period. Blood was collected after three weeks, and the serum antibody titer was confirmed by ELISA.
[0098] The ELISA procedure was as follows: The antigen protein was dispensed onto Immunoplate Maxisorp (442404, Thermo Fisher) at 50 ng / well and immobilized. After blocking with 5% skim milk (Difco, 232100) / TBS-T (50 mM Tris-HCl (pH 7.4), 0.14 M NaCl, 0.05% Tween 20), serum diluted 1 / 2,000, 1 / 8,000, 1 / 32,000, or 1 / 128,000 with TBS-T was added and reacted. Subsequently, anti-IgG (Fc), human, goat-poly, HRP (A80-104P, Bethyl) diluted 1 / 50,000 with TBS-T was added and reacted, followed by color development with 0.5 mg / mL o-phenylenediamine and quenching with 1 M sulfuric acid. Finally, absorbance at 492 nm was measured, and the antibody titer was calculated.
[0099] As a result, an increase in antibody titer was confirmed in all immunized individuals ( FIG. 15 ). The individual with the highest antibody titer among the five (individual number: 7484) was used in the cell fusion experiment.
[0100] b: Cell fusion. Cells were collected from the spleen and iliac lymph nodes of individual number 7484 and counted. The cells were suspended in electrofusion electrode solution (0.3 M mannitol, 0.1 mM CaCl2, 0.1 mM MgCl2) and mixed with an equal number of myeloma cells (P3X63Ag8.653) similarly suspended in electrofusion electrode solution. The cells were fused using a cell fusion device (ECFG21, Nepa Gene), seeded into 96-well plates in medium containing HAT (H0262-10VL, Merck), and selectively cultured for two weeks.
[0101] c: Screening: Antigen proteins expressed in E. coli were dispensed onto Immunoplate Maxisorp (442404, Thermo Fisher) at 50 ng / well and immobilized. After blocking with 5% skim milk (Difco, 232100) / TBS-T (50 mM Tris-HCl (pH 7.4), 0.14 M NaCl, 0.05% Tween 20), hybridoma culture supernatant diluted 2 / 3 with TBS-T was added and reacted. Subsequently, anti-IgG (Fc), human, goat-poly, and HRP (A80-104P, Bethyl) diluted 1 / 50,000 with TBS-T was added and reacted. Color development was performed with 0.5 mg / mL o-phenylenediamine, and the reaction was stopped with 1 M sulfuric acid. Finally, the absorbance at 492 nm was measured and screening was performed (primary screening). Hybridoma colonies were picked from wells that were positive in the primary screening. After culturing for 2 to 3 days, the culture supernatant was collected and screened by ELISA in the same manner as in the primary screening (secondary screening).
[0102] d: Cloning The hybridoma cells of the top 10 clones with the highest absorbance obtained in the secondary screening were cloned using the limiting dilution method. Screening of positive wells was performed by ELISA, as in the primary screening. Cloning was repeated until single colony positive wells were obtained at least twice, and six clones with high antibody titers (identification numbers: #002, 003, 007, 008, 009, and 010) were selected from the 147 positive hybridomas and used for antibody purification ( FIG. 16 ).
[0103] e: Antibody purification. Hybridoma cells with identification numbers #002, 003, 007, 008, 009, and 010 were cultured in 100 mL of serum-free medium for two weeks, and the culture supernatant was collected. Antibody purification was carried out using Protein G Sepharose (Cytiva) according to the method described in the package insert. After purification, the antibody was concentrated using an ultrafiltration membrane, and the solvent was replaced with DPBS(-).
[0104] Purification of the antibody was confirmed by SDS-PAGE ( FIG. 17 ). Furthermore, the antibody titer was confirmed by ELISA ( FIG. 18 ). The identification numbers #002, 003, 007, 008, and 010, which were among the top five antibody titers, were used for Western blot analysis.
[0105] 6. Western Blot Study The five antibody clones were examined to determine whether they could detect COPB2 protein in human and mouse cells by Western blotting. Specifically, 10 μg of cell extract prepared from human HEK293 cells using RIPA lysis solution (Santa Cruz Biotechnology) and 5 and 10 μg of tissue extract prepared from mouse liver using T-PER lysis solution (ThermoFisher Scientific) were subjected to SDS-PAGE under reducing conditions and then transferred to an Immobilon-P membrane (Merck Millipore). Blocking was performed for 1 hour at room temperature using TBS-T (0.05 M Tris-HCl, 0.15 M NaCl, 0.05% Tween 20, pH 7.6) containing 3% skim milk, and the membrane was then reacted overnight at 4°C with a solution of each antibody dissolved in TBS-T containing 3% skim milk at a concentration of 1 μg / mL. After the reaction, each membrane was washed three times with TBS-T for 10 minutes each, then incubated with a 1:1000 dilution of HRP-labeled rabbit anti-mouse IgG polyclonal antibody (Dako) in TBS-T containing 3% skim milk at 4°C for 2 hours. After washing three times with TBS-T for 10 minutes, the membranes were detected using ChemiLumiOne Super (Nacalai Tesque) (Figure 19). The results indicated that all antibodies reacted strongly with human COPB2, and all antibodies except for #003 and #008 also cross-reacted with mouse COPB2. Furthermore, #010 was confirmed to react strongly with both human and mouse COPB2. Furthermore, #002 and #007 were confirmed to react more strongly with mouse COPB2 than with human COPB2.
[0106] 7. Isotype Analysis and CDR Analysis The procedure for isotype analysis is as follows. Specifically, purified antibodies with identification numbers #003 and #010 were diluted to 2 μg / mL with D-PBS(-) and 100 μL each was added to the cassette of a human isotyping kit (ISO-Hu-20, Antagen). As a result, the subclass of identification numbers #003 and #010 was confirmed to be IgG1 / kappa (Figure 20).
[0107] The CDR analysis procedure was as follows. Specifically, hybridoma cells with identification numbers #003 and #010 were cultured in 10 cm dishes until confluent. The cells were then centrifuged to collect cell pellets, which were then subjected to RNA extraction. RNA extraction was performed using NucleoSpinRNA Plus (Takara Bio Inc.) according to the method described in the package insert. The extracted RNA was reverse transcribed using SMARTer RACE 5' / 3' Kit (Takara Bio Inc.) according to the method described in the package insert to obtain cDNA. The obtained cDNA was ligated to a pRACE sequence (Takara Bio Inc.) to prepare an expression vector. The obtained expression vector was cloned in Escherichia coli according to standard methods, and the CDR sequence was analyzed by sequencing the purified plasmid. The amino acid sequences of the heavy chain CDR1 to 3 and light chain CDR1 to 3, as well as the heavy chain variable region and light chain variable region of human monoclonal antibodies #003 and #010, are shown in Figures 13 and 14.
[0108] 8. Study of anti-COPB2 antibody administration to breast cancer cells a) Cell viability and apoptosis induction (caspase 3 / 7 activity) Human triple-negative breast cancer cell line MDA-MB-231-luc-D3H2LN (Xenogen, Inc.) was seeded at a density of 2,000 cells / well in 96-well plates in 0.5 mL serum-free medium and cultured. After 24 hours of culture, the medium was replaced with medium containing fully human monoclonal antibodies TA201B010a and TA201C003a at concentrations of 5 μM or 20 μM, and PBS (-) as a control. After an additional 72 hours, cell viability and caspase 3 / 7 activity were measured using the ApoLive-Glo Multiplex Assay Kit according to the instructions in the package insert. b) Results: For human breast cancer cells (MDA-MB-231-luc-D3H2LN), the presence of a 20 μM concentration of the fully human monoclonal antibody (TA201B010a clone) significantly reduced viability (Figure 10). Similarly, caspase 3 / 7 activity was significantly reduced in the presence of both the TA201B010a clone and the TA201C003a clone at 20 μM (Figure 10). This suggests that anti-COPB2 antibodies have the effect of inducing cell death in breast cancer cells, but it is speculated that this cell death occurs through a process independent of caspase activity.
[0109] 9. Study of administration of anti-COPB2 antibody to breast cancer model mice a) Creation of breast cancer model mice Human triple-negative breast cancer cell line MDA-MB-231-luc-D3H2LN (Xenogen, Inc.) was inoculated into 8 × 10 7 cells+2ml (PBS 0.5ml: MatriMix 1.5ml), 4 x 10 7The cells were adjusted to 2 × 10 cells / ml (MatriMix was prepared on ice to a ratio of solution A:solution B:solution C = 5.4:0.6:4.0), and injected into the subcutaneous adipose tissue around the right inguinal nipple of a Scid-Beige mouse (Jackson Laboratory Japan, female, 6 weeks old). 6 Cells were transplanted to create breast cancer model mice. b) Administration of anti-COPB2 antibody Anti-COPB2 antibody (anti-COPB2 monoclonal antibody A2-7C6) was administered at 50 μg / 0.1 mL / mouse via the tail vein on days 5, 8, 11, 14, and 17 after cell transplantation. As a control, the same volume of PBS was administered (n=8). c) Evaluation 1 To examine changes in the luminescence intensity derived from breast cancer cells, measurements were performed using IVIS (PerkinElmer, Inc., IVIS Lumina-LT) on days 7, 14, 21, 28, and 37 after transplantation. The FOV (field of view, camera height) was 12.5, f1.2, the measurement time was 30 seconds, and the binning (sensitivity) was set to 8 or 4. Analysis was performed using LivingImage, version 4.7.3, and the luminescence intensity was quantified. The results are shown in Figure 7. The luminescence intensity of the whole body of the mice measured weekly using IVIS after the transplantation of human breast cancer cells was significantly higher in the anti-COPB2 antibody-administered group than in the PBS(-)-administered group at 3 and 4 weeks, but by 5 weeks, the situation reversed, with the luminescence intensity tending to be lower in the anti-COPB2 antibody-administered group. d) Evaluation 2: At 5 weeks (day 37), breast cancer model mice were euthanized and the primary tumor was removed. The luminescence intensity of the primary tumor and the whole body of the breast cancer model mice after primary tumor removal was measured. The results are shown in Figures 8 to 11. In the primary tumor and in the whole body of the breast cancer model mice after primary tumor removal, the anti-COPB2 antibody administration group showed significantly lower luminescence levels and a trend toward a decrease in the number of metastatic lesions. These results demonstrate that administration of the anti-COPB2 antibody reduced the size of the transplanted primary tumor and inhibited cancer metastasis.
Claims
1. A pharmaceutical composition for treating or preventing cancer, comprising an antibody or an antigen-binding fragment thereof against coatomer protein complex subunit beta 2 (COPB2).
2. The pharmaceutical composition of claim 1, wherein the cancer is a primary tumor.
3. The pharmaceutical composition according to claim 1 for suppressing the recurrence of cancer.
4. The pharmaceutical composition according to claim 1 for inhibiting cancer metastasis.
5. The pharmaceutical composition according to claim 1, wherein the cancer is one or more selected from the group consisting of breast cancer, glioma, gastrointestinal cancer, hepatocellular carcinoma, liver cancer, prostate cancer, lung cancer, and pancreatic cancer.
Citation Information
Patent Citations
Antibody against coatomer protein complex subunit beta 2
WO2024101357A1
